Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide

drug protocol number

80202135EBF3001

drug sponsor

Janssen-Cilag International NV

drug study

Talquetamab

drug trial site

King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh)

drug status

Ongoing

drug phase